Plus Therapeutics (PSTV)
(Delayed Data from NSDQ)
$1.37 USD
+0.07 (5.38%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.39 +0.02 (1.46%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
PSTV 1.37 +0.07(5.38%)
Will PSTV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PSTV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PSTV
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
PSTV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PSTV
Plus Therapeutics files for $100M mixed securities shelf
Plus Therapeutics files $100M mixed securities shelf
Biotech Alert: Searches spiking for these stocks today
Buy Rating Affirmed for Plus Therapeutics Amidst ReSPECT-GBM Trial Progress and Overlooked Market Potential
Plus Therapeutics' Rhenium Obisbemeda shows safety, potential efficacy